FDA Expands Inspections at Foreign Manufacturing Plants

On Tuesday, the U.S. Food and Drug Administration (FDA) revealed plans to increase unannounced inspections at foreign facilities producing food and drugs for American consumers.

This initiative builds on a pilot program already in progress, which has seen unannounced inspections in countries like India and China.

“For too long, foreign companies have enjoyed a double standard. They receive advance notifications before inspections, while American manufacturers are held to strict standards without such notice. That changes today,” an FDA spokesperson stated.

This announcement was hinted at during a press conference on Monday, where discussions included an executive order related to research on function gains.

“There’s this odd situation in the U.S. where American pharmaceutical manufacturers face stringent inspections while foreign sites get scheduled visits quite easily,” the spokesperson noted.

The FDA’s announcement mentioned that, in addition to roughly 12,000 tests conducted domestically, the agency performs about 3,000 inspections abroad each year, covering over 90 countries. Despite advance notifications to foreign companies, severe issues have been discovered abroad at more than double the rate compared to domestic findings.

Interestingly, reports suggest that, despite media attention, FDA officials are considering cuts to support staff, leading to a potential reduction in overall testing efforts.

The agency has already reduced its staff by 170, affecting its travel operations division and various federal health officials. This restructuring was highlighted in a CBS News report earlier in April.

“Going forward, frontline investigators will be dedicating more time to managing travel and related tasks instead of focusing on ensuring consumer safety,” an official stated.

The FDA is still addressing a backlog of inspections that developed during the Covid-19 pandemic.

According to a Government Accountability Office (GAO) report, the employment situation at the FDA is challenging, partly due to the retirement of seasoned inspectors.

Currently, the U.S. imports about 15% of its total food supply from abroad, according to the FDA. However, the drug manufacturing landscape tells a different story.

In 2018, over 60% of drug manufacturers supplying the U.S. market were based overseas. The country is especially reliant on China for antibiotics, with Chinese-produced active pharmaceutical ingredients comprising nearly 90% of the antibiotics available in the U.S.